MAPT and Alzheimer disease: The ICV STZ-administered mice develop impairment of memory, advanced cholinergic discrepancies, hypometabolism of glucose in the brain, and oxidative stress, along with degeneration of neurons that leads to AD, which is associated with aggregated Aβ plaques, tau protein, and Aβ deposits.